SCHEMBL5541914

SCHEMBL5541914

[CH2]c1ccccc1-c1ccccc1OC(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
HSD11B1 P28845 1/20 0.43
KCNN4 O15554 1/20 0.41
SCN9A Q15858 5/20 0.41
POLB P06746 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TRPA1 O75762 1/20 0.41
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
SCN10A Q9Y5Y9 1/20 0.39
CNR2 P34972 1/20 0.38
S1PR1 P21453 1/20 0.37
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
MPL P40238 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7701143 0.87 ALDH1A1 (0.50) ALDH1A1L3MBTL1HSD11B1KCNN4SCN9A
SCHEMBL96142 0.83 GAA (0.38) ALDH1A1L3MBTL1HSD11B1SCN9APOLB
SCHEMBL2095253 0.77 FFAR4 (0.50) ALDH1A1L3MBTL1HSD11B1SCN9ATRPA1
SCHEMBL2955033 0.76 S1PR1 (0.56) ALDH1A1L3MBTL1HSD11B1KCNN4SCN9A
SCHEMBL398120 0.76 ALDH1A1 (0.52) ALDH1A1L3MBTL1HSD11B1KCNN4SCN9A
SCHEMBL27470653 0.76 ALDH1A1 (0.46) ALDH1A1L3MBTL1HSD11B1KCNN4SCN9A
SCHEMBL27660142 0.76 HSD11B1 (0.62) ALDH1A1L3MBTL1HSD11B1KCNN4SCN9A
SCHEMBL27661562 0.76 KDM4E (0.34) ALDH1A1L3MBTL1HSD11B1SCN9APOLB
SCHEMBL29788132 0.75 FFAR4 (0.55) ALDH1A1L3MBTL1HSD11B1SCN9ATRPA1
SCHEMBL306822 0.75 FFAR4 (0.55) ALDH1A1L3MBTL1HSD11B1SCN9ATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885L3MBTL1 1931/4885HSD11B1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.